Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C105612
http://purl.obolibrary.org/obo/NCIT_C105612
|
|---|---|
| Preferred Name | Depatuxizumab Mafodotin |
| Definitions |
An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, depatuxizumab mafodotin inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed in certain tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, depatuxizumab mafodotin inhibits the activity of EGFR, thereby preventing EGFR-mediated signaling. This may inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase overexpressed in certain tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. |
|---|---|
| prefLabel | Depatuxizumab Mafodotin
|
| label | Depatuxizumab Mafodotin
|
| NCI_META_CUI | CL446449
|
| PDQ_Closed_Trial_Search_ID | 747249
|
| code | C105612
|
| Has_Target | |
| prefixIRI | NCIT:C105612
|
| in_subset |
See more
See less
|
| Display_Name | Depatuxizumab Mafodotin
|
| Preferred_Name | Depatuxizumab Mafodotin
|
| FDA_UNII_Code | F3R7A4P04N
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Depatuxizumab Mafodotin
|
| CAS_Registry | 1585973-65-4
|
| NCI_Drug_Dictionary_ID | 747249
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 747249
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |